Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting

Affiliations

• ¹ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte. Electronic address: hrugo@coh.org.
• ² The University of Texas MD Anderson Cancer Center, Houston, USA.
• ³ Dana-Farber Cancer Institute, Boston, USA.
• ⁴ Pfizer Inc., New York, USA.
• ⁵ Flatiron Health Inc., New York, USA; NYU Langone School of Medicine, New York, USA.
• ⁶ Flatiron Health Inc., New York, USA.
• ⁷ European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
• ⁸ UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, USA.